INTRODUCTION
Several investigators have evaluated the diagnostic value of amniotic fluid (AF)-specific polypeptides or metabolites as indicators of obstetrical disorders, including premature rupture of membranes (PROM) [1] [2] [3] [4] or amniotic fluid embolism (AFE) [5] [6] [7] [8] [9] [10] . We have conducted a document retrieval to identify gene products that are specifically present only in AF but not present in the maternal serum (MS) or proteins/polypeptides that are present in AF at concentrations extremely higher than those in the MS. Proteomic technologies have been predominantly used in the research to discover new AFspecific markers [11] [12] [13] [14] [15] . We have previously reported many candidate markers [16] . Enriched protein functions were tumor markers, cell proliferation and embryonic development, metabolism, nervous system, cytokines, immune or complement processes, signaling, cell adhesion and motility, hormones, detoxification system, and metal carrier [16] .
In the present study, among these candidate markers, the following six antigens, interleukin (IL)-6, insulin-like growth factor-binding protein (IGFBP)-1, osteopontin (OPN), Squamous cell carcinoma (SCC) antigen, CA125 and sialosyl Tn (STN), were selected, since the specific ELISA has been commercially available. We have examined if these proposed markers are over expressed specifically in AF and if their concentration changes with the presence of labor.
MATERIALS AND METHODS

Study Population and AF Collection
Twenty-six healthy women who gave birth to healthy newborns at term during the period from July 2009 to January 2010 at the Nara Medical University Hospital, Nara, Japan, were included in the study. Pregnant women who presented to our hospital were asked to participate. Two groups of women were recruited: 1) 7 term pregnant women (gestational age, 37 -41 wk) carrying a single fetus and undergoing elective cesarean section before labor, whose peripheral bloods were taken just prior to operation (term maternal blood); 2) 9 term pregnant women undergoing elective cesarean section before labor, whose amniotic fluids were taken (AF without labor); 3) 10 similar term pregnant women undergoing emergency cesarean section after spontaneous labor (all women were in the active phase of labor of less than 5 minutes interval), whose amniotic fluids were taken (AF with labor). The main indications for urgent and emergency cesareans were prolonged labor and presumed fetal compromise. Subjects with any symptom of infection were excluded from the study. No subject had a comorbid condition such as hypertension, diabetes, asthma, congenital heart disease, kidney disease, connective tissue disorders, and autoimmune disease. All neonates had normal anatomies. This study was approved by the Nara Medical University ethics committee. Informed consent was obtained from all mothers. Clinical data were obtained by two investigators (K.N. and T.N.) and recorded using a standardized data sheet. The women's ages, gestational ages, and parity did not differ significantly between the three groups.
Sampling
Maternal blood was obtained from a cannulated vein a few minutes prior to surgery. AF was obtained during surgery by one investigator (K.N.) and immediately filtered through 0.45 μm pore filter (Millex, Millipore Co. Ltd., Billerica, MA) to avoid the debris. After centrifugation at 4˚C, MS and AF were immediately frozen and stored at −80˚C until further analysis. OPEN ACCESS IGFBP-1 (27.09 ± 9.86 μg/ml for without labor and 135.67 ± 44.45 μg/ml for with labor, p < 0.05), SCC (240.08 ± 57.03 ng/ml for without labor and 451.58 ± 178.15 ng/ml for with labor), osteopontin (480.32 ± 144.87 ng/ml for without labor and 611.54 ± 217.00 ng/ml for with labor), CA125 (491.12 ± 62.21 U/ml for without labor and 840.70 ± 186.64 U/ml for with labor), and STN (108.63 ± 98.57 U/ml for without labor and 191.05 ± 107.76 U/ml for with labor). Serum level of each marker was not markedly elevated and below the cut-off value. Very high AF/MS ratio was found in IL-6 (AF/MS = 395 for without labor and 2811 for with labor), followed by SCC (AF/MS = 179 for without labor and 336 for with labor), IGFBP-1 (AF/MS = 9 for without labor and 47 for with labor), CA125 (AF/MS = 24 for without labor and 41 for with labor), osteopontin (AF/MS = 9 for without labor and 11 for with labor), and STN (AF/MS = 4 for without labor and 8 for with labor). The AF/MS measurement based on IL-6 or SCC has proved to be superior to IGFBP-1, CA125, osteopontin, and STN. Patients after labor showed significantly higher IL-6 and IGFBP-1 concentrations in AF compared with women before labor. Comparison of AF SCC levels between before and after labor was not significant. Osteopontin, STN and CA125 in AF and MS did not also change significantly with or without labor.
Measurements of Six Biomarker Levels in Maternal Serum and Amniotic Fluid
RESULTS
DISCUSSION
Gene expression profiling and proteomics analyses were used to analyze biological samples to identify the AFspecific genes and their products. Many candidates have been discovered and reported as shown in reference [16] . In the present study, AF and MS were collected at term, either before (elective caesarean section) or after the onset of labor (emergency caesarean section). We found that IL-6 and SCC are present in AF at concentrations extremely higher than those in the MS (11, 14) . It appears likely that both are AF-specific proteins.
The AF IL-6 levels increase in late gestation. A role in regulation of labor onset is suggested by observations that IL-6 up-regulates expression of genes controlling prostaglandin synthesis and signaling [17] . IL-6 might be produced by macrophages, mast cells, trophoblasts, decidua cells and amniotic fluid cells [18] . There is strong evidence that IL-6 in AF is a clinically useful test to predict preterm birth [19] . IL-6 might increase with both types of labor, preterm and term, with a greater change at the onset of labor.
On the other hand, the AF SCC levels were significantly higher and did not change with the onset of labor. In uncomplicated pregnancies, MS SCC levels at term gestation were similar to nonpregnant levels. To date, the exact source and biological role of elevated antigens are not clearly defined. Further work is necessary to evaluate the biological function of SCC for preterm and term labor.
Among the marker used in clinical practice, several investigators have evaluates the diagnostic value of IGFBP-1 as an indicator of PROM. However, contamination of the cervicovaginal samples by maternal blood can induce false positive results. The IGFBP-1 levels in MS at term are >1000 ng/ml, whereas the SCC concentrations are <5 ng/ml. The SCC test might be unaffected by contamination. SCC may have high predictive values for diagnosing PROM.
In addition, since AFE is a dramatical complication in pregnancy that occurs when AF enter the maternal circulation, the method for detecting the AF-specific antigens such as IL-6 and SCC in the MS may be a novel method for diagnosis of AFE. If AFE was verified by medicolegal autopsy, immunostaining for IL-6 or SCC in the affected lung may be a sensitive method to confirm AFE patients because these antibodies are commercially available. These markers would become the favorable biomarkers for detecting AFE. The test based on IL-6 or SCC seems to be a more sensitive bedside test compared with the conventional tests based on STN for the detection of entry of AF into maternal circulation (9, 10) .
A limitation of this study should be noted. The sample size and small number may have limited our ability to detect small differences. So far, we have never determined the cervicovaginal fluid or MS levels in patients with PROM or AFE, respectively. Notwithstanding these limitations, our observation of SCC and IL-6 in AF opens a new area of research to assess their usefulness as biological markers of PROM or AFE. The future clinical study will evaluate whether or not each proposed marker is ready for clinical applications. Larger and validation studies are also needed to determine the true value of these new biomarkers.
ACKNOWLEDGEMENTS
Supported by a grant (Grant-in-aid for Scientific Research (H. Kobayashi, H. Oi and K. Naruse)) from the Ministry of Education, Science, and Culture of Japan and by a grant from Alfresa Pharma Corporation (2-2-9 Kokumachi, Chuo-ku, Osaka 540-8575, Japan (H. Kobayashi and K. Naruse)).
